Core Viewpoint - The announcement of the New Drug Application (NDA) acceptance for denifanstat (ASC40), a first-in-class oral small molecule fatty acid synthase (FASN) inhibitor for the treatment of moderate to severe acne, marks a significant milestone for the company in providing a potentially groundbreaking therapy for acne treatment [1][2]. Group 1 - The NDA for denifanstat (ASC40) has been accepted by the National Medical Products Administration (NMPA) of China [1]. - The company has completed Phase II (NCT05104125) and Phase III (NCT06192264) studies for denifanstat (ASC40) in treating moderate to severe acne [1]. - The Phase III study demonstrated that denifanstat (ASC40) achieved all primary, key secondary, and secondary efficacy endpoints, significantly improving moderate to severe acne compared to placebo [2]. Group 2 - Denifanstat (ASC40) exhibited good safety and tolerability, with all treatment-emergent adverse events (TEAEs) being mild (Grade 1) or moderate (Grade 2) [2]. - There were no Grade 3 or 4 TEAEs related to denifanstat (ASC40), nor were there any serious adverse events (SAEs) associated with the treatment [2]. - The company has received positive feedback from the NMPA following recent pre-NDA communications regarding the new drug application for denifanstat (ASC40) [2]. Group 3 - The company has obtained exclusive rights for denifanstat (ASC40) in the Greater China region from Sagimet Biosciences Inc. (NASDAQ: SGMT) [2]. - The results of the Phase III study were presented orally at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting held in Paris [2].

Core Viewpoint - The announcement of the acceptance of the New Drug Application (NDA) for the first-in-class oral small molecule fatty acid synthase (FASN) inhibitor, ASC40, by the National Medical Products Administration (NMPA) of China marks a significant milestone in providing a potential groundbreaking therapy for moderate to severe acne [1] Company Summary - The company, Gilead Sciences-B (01672.HK), is advancing its innovative treatment for moderate to severe acne with the drug ASC40, which is a first-in-class FASN inhibitor [1] - The CEO, Dr. Wu Jinzi, expressed excitement about the NDA acceptance, indicating that ASC40 is just one step away from commercialization [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） － 在一項隨機、雙盲、安慰劑對照、多中心的III期臨床試驗中，地尼法司他 (ASC40)達到所有主要、關鍵次要及次要療效終點（意向治療集(ITT)分析）， 與安慰劑相比顯著改善中重度尋常性痤瘡。 （股份代號：1672） 自願性公告 歌禮宣佈同類首創FASN抑制劑地尼法司他(ASC40)治療痤瘡的 新藥上市申請獲中國國家藥品監督管理局受理 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈同類首創(first-in-class)、每日一次口服小 分子脂肪酸合成酶(FASN)抑制劑地尼法司他(ASC40)治療中重度尋常性痤瘡的新 藥上市申請(NDA)獲中國國家藥品監督管理局（國家藥 ...

Group 1 - Hong Kong stocks experienced a decline, with the Hang Seng Index dropping 109 points or 0.43% to 25,325 points amid mixed performances from major tech stocks [1] - Alibaba (09988) aims to develop a super app through its newly established C-end business group, resulting in a 0.6% increase in its stock price [1] - Semiconductor stocks faced downward pressure, with SMIC (00981) down 1.7% and ASMPT (00522) down 3.2%, while the U.S. government allows NVIDIA to export H200 AI chips to China, but the Chinese government reportedly plans to restrict access to these chips [1] Group 2 - Automotive stocks showed weakness, with BYD (01211) down 1.1% and NIO (09866) down 2.8%, while Geely (00175) plans to secure a $420 million syndicated loan for the privatization of Zeekr, leading to a 0.9% increase in its stock price [2] - Shipping stocks saw significant declines, with the Baltic Dry Index (BDI) hitting a near two-week low, causing Orient Overseas International (00316) to drop 5.6% [2] - Pharmaceutical stocks were mixed, with China National Pharmaceutical Group (01177) and others declining by 2.5% to 3.3%, while Fosun Pharma (02196) rose by 3.8% [2] Group 3 - The Hong Kong market sentiment has turned cautious as southbound trading has been shrinking, with the upcoming Central Economic Work Conference expected to provide further guidance [3] - The Federal Reserve's interest rate decision is anticipated to impact Hong Kong stocks, with potential support for the market if a hawkish stance is not adopted [3]

➢ 每日大市点评 12 月 9 日，投资者观望本周美联储议息结果，港股升势乏力。恒生指数高开后一路下跌，收盘下跌 331 点（1.3%），收 报 25,434 点；恒生科技指数下跌 107 点（1.9%），收盘报 5,554 点；全天大市成交额微增至 2,102 亿元。港股通净流入 减少至 5.3 亿元。盘面上，美国国会料通过法案，限制中资生物科技公司获得华府资助合约，生物科技医药股逆市造好， 药明生物（2269 HK）升 1.9%；药明康德（2359 HK）升 1.1%。特朗普允许英伟达向中国出售 H200 芯片，港股芯片板块 下跌，中芯国际（981 HK）和华虹半导体（1347 HK）下跌 4%-5%。内房股方面，雅居乐（3383 HK）被提出清盘呈请， 周二跌 18.4%，其他内房股受到拖累，龙湖（960 HK）跌 6%；华润置地（1109 HK）跌 3.7%；中海外（688 HK）跌 3.1%。 港股短期将维持震荡格局。 2025 年 12 月 10 日 星期三 国家统计局将于 12 月 10 日公布 11 月物价数据。市场预期，11 月食品价格上行将推动当月全国居民消费价格（CPI）同 比增速回升； ...

Core Viewpoint - WuXi Biologics (02269) has shown a fluctuating upward trend in its stock price, currently at 33.74 HKD, up 0.42%, with a five-day volatility of 11.4%, indicating active market trading and some volatility [1] Group 1: Stock Performance - The biotechnology sector is experiencing a strong performance against the market trend, with several Chinese biotech stocks performing well despite the Hang Seng Index decline on December 10, 2025 [1] - Other related companies such as WuXi AppTec (02359) and China Biologic Products (01177) saw declines of 1.15% and 2.04%, respectively [1] - Notably, the stock of Gilead Sciences (01672) surged nearly 18% due to positive results from its obesity treatment drug research, but later dropped by 3.73% [1] Group 2: Technical Analysis - WuXi Biologics' stock price is currently near the 10-day moving average (approximately 32.03 HKD) and the 30-day moving average (approximately 33.17 HKD), slightly below the 60-day moving average (approximately 35.78 HKD) [1] - The Relative Strength Index (RSI) is at a neutral level of 52, with overall technical indicators signaling a "neutral" stance, while some trend indicators like MACD and Bollinger Bands are giving buy signals [1] - Key support levels are at 31.9 HKD and 31 HKD, while resistance levels are at 35.2 HKD and 36.1 HKD, with an overall upward probability of 54% [3] Group 3: Derivative Market Insights - The performance of derivative products has been notable, with leveraged characteristics highlighted in a volatile market [4] - On December 5, when WuXi Biologics' stock rose approximately 2.88%, related derivative products showed significant price changes, with UBS bull certificates (67145) rising 18% and JPMorgan bull certificates (66081) increasing by 14% [4] - This demonstrates that even moderate increases in the underlying stock can lead to amplified returns in derivatives due to leverage [4][5] Group 4: Investment Strategies - For investors considering derivatives, various products are available to meet different investment strategies and risk preferences [7] - UBS bull certificates (67145) have a strike price of 28.8 HKD and an actual leverage of about 5 times, providing a safety margin due to its distance from the current stock price [7] - For cautious investors, UBS bear certificates (58905) with a strike price of 40 HKD and an actual leverage of about 4.6 times may serve as a hedging option [7]

Summary of Key Points from the Conference Call Industry Overview - The weight loss sector is expected to diversify by 2026, with multinational pharmaceutical companies accelerating their investments and new technologies rapidly evolving to address the shortcomings of existing GLP-1 drugs, such as adherence, efficacy, and safety issues. Oral, multi-target, and monthly dosing are emerging as significant trends [1][4]. Core Insights and Arguments - **Clinical Trial Results**: - Gilead's oral GLP-1 drug showed a 7.7% weight loss effect in the 60 mg dose group during Phase I trials in the U.S., outperforming Eli Lilly's similar products with better safety [1][5]. - Shodai's Phase II trials indicated an 11.3% weight loss in the 120 mg dose group, although with higher adverse reactions, prompting optimization of the titration scheme [1][5]. - **Strategic Collaborations**: - Pfizer and Fosun Pharma entered a collaboration for an oral GLP-1 receptor agonist, with an upfront payment of $150 million and a total deal value of $2 billion, highlighting China's leading position in this field and attracting international attention [1][6]. - **Market Dynamics**: - GLP-1 drugs like semaglutide and tirzepatide are experiencing significant sales growth, becoming billion-dollar products. Companies like Sody and Beifu have seen stock price surges following data updates [2]. Emerging Trends - **Focus Areas**: - Key focus areas in the weight loss sector include improving adherence (oral products), enhancing efficacy (multi-target combination therapies), and optimizing safety [1][7]. - **Innovative Approaches**: - New generation oral products are expected to offer greater convenience, with dosing frequency shifting towards monthly administration. Innovations are also being explored to enhance efficacy and safety, such as using dual receptor monoclonal antibodies or small nucleic acids to preserve muscle mass and reduce gastrointestinal side effects [4][16]. Notable Companies and Developments - **Gilead and Shodai**: - Gilead's new oral GLP-1 receptor agonist and Shodai's ongoing trials are highlighted as significant opportunities for investment [1][7]. - **Federal Pharmaceuticals**: - The company has licensed UBT251 to Novo Nordisk for $185 million, with overseas clinical trials expected to start in Q1 2026 [2][10]. - **Amy Target Developments**: - Eli Lilly's Elon Limited is set to present Phase II data at Obesity Week, showing promising safety and efficacy results, which could position it as a significant player in the market [11][12]. Future Outlook - **Market Predictions**: - The weight loss sector is anticipated to continue evolving with more significant business development transactions and innovations in drug delivery methods, particularly monthly dosing technologies [4][15]. - **Investment Opportunities**: - Companies like Gilead and Shodai are recommended for their potential breakthroughs in the GLP-1 space, while the multi-target weight loss sector is also gaining traction with promising clinical data [1][7][10]. Additional Insights - **Polypeptide Industry Growth**: - The polypeptide supply chain is rapidly developing, with increasing demand driven by pricing strategies from major players like Novo Nordisk and Eli Lilly, which are expected to enhance market access and approval processes [17].

神舟二十一号航天员乘组圆满完成第一次出舱活动 男生普通话版 下载mp3 女声普通话版 下载mp3 粤语版 下载mp3 西南方言版 下载mp3 东北话版 下载mp3 上海话版 下载mp3 今日优选 特朗普：可能降低部分价格过高的商品关税 英媒：特朗普本周启动美联储主席人选的最后一轮面试 英媒：特朗普"施压"泽连斯基几日内回应和平提议 泽连斯基首次松口愿意选举 据悉SpaceX拟以1.5万亿美元估值进行IPO 李强分别会见世界银行、国际货币基金组织、联合国贸易和发展会议负责人 摩尔线程：即将发布新一代GPU架构 市场盘点 周二，美国就业市场数据好于预期，美元指数走高，最终收涨0.14%，报99.24；基准的10年期美债收益率最终收报4.1900%，对美联储政策利率敏感的2年期 美债收益率收报3.6250%。 交易员对美联储降息保持乐观，现货黄金震荡上行，最终收涨0.39%，报4206.59美元/盎司；现货白银在供应紧张的情况下首次达到60美元的里程碑，最终 大涨4.34%，报60.67美元/盎司。 受伊拉克生产恢复的影响，国际油价连续两日走低，WTI原油最终收跌0.78%，报58.28美元/桶；布伦特原油最终收跌 ...

Market Overview - The Hong Kong stock market indices declined again, with the Hang Seng Index falling 1.29% to 25,434.23 points and a total trading volume of HKD 210.236 billion [1] - The decline in the Hong Kong market is attributed to several factors, including a shrinking southbound capital flow, concerns over potential interest rate hikes by the Bank of Japan, and expectations that the Federal Reserve's upcoming rate cut may not be as dovish as anticipated [1] Blue Chip Performance - WuXi Biologics (02269) led the blue-chip stocks, rising 1.88% to HKD 33.56, contributing 3.64 points to the Hang Seng Index [2] - Other notable blue-chip performances included China Biologic Products (01177) up 1.33% and WuXi AppTec (02359) up 1.06%, while Xinyi Glass (00868) fell 8.11% and Chow Tai Fook (01929) dropped 4.82% [2] Sector Movements - Large technology stocks experienced declines, with Alibaba down 1.63% and Tencent down 0.41%. Chip stocks fell collectively after the announcement allowing NVIDIA to sell H200 chips to China, with SMIC down over 4% [3][5] - The real estate sector saw significant declines, particularly with Agile Group (03383) dropping 18.42% amid a court liquidation petition [4] - Industrial metals stocks, including Jiangxi Copper (00358) and China Aluminum (02600), faced notable declines, with Jiangxi Copper down 6.51% [3][4] Notable Company Developments - China Metallurgical Group (01618) saw a significant drop of 21.01% after announcing a cash transaction to sell its subsidiaries for approximately HKD 60.7 billion [6] - Gilead Sciences (01672) surged 18% following positive results from a clinical trial for its obesity treatment, with Citigroup expecting a positive market reaction [7] - E-Hi Auto (02858) rose 10.67% after renewing a strategic cooperation agreement with Tencent's subsidiary for used car services [8]

市场等待本周美联储议息会议，港股三大指数今日再度走低，恒指及国指均跌超1%，恒科指数一度跌 超2%。截止收盘，恒生指数跌1.29%或331.13点，报25434.23点，全日成交额为2102.36亿港元；恒生国 企指数跌1.62%，报8936.41点；恒生科技指数跌1.9%，报5554.68点。 中金指出，关于近期港股为何在三地中走得更弱，资金面上可以找到一些解释：1）南向过去几周持续 萎缩，港股不在基准的话可能导致调仓；对比之下，港股IPO 一点不少，且上半年集中上市的大票纷纷 到了6个月解禁期；2）日央行下周加息担忧挥之不去；3）美联储本周虽然降息，但觉得也很难鸽派， 所以美债利率不降反升，诸如此类。 蓝筹股表现 药明生物(02269)领涨蓝筹。截至收盘，涨1.88%，报33.56港元，成交额14.34亿港元，贡献恒指3.64点。 交银国际指，2025年CXO整体订单和业绩复苏势头明显。该行预计，随着下游融资边际改善+出海热潮 带动上游景气度逐步进一步回升，2026年板块有望维持较快的业绩增速。但在美国药品相关监管收紧、 新药研发难度升级的长期大趋势下，行业整合或才刚拉开序幕，未来将继续淘汰落后产能及企业 ...